Admedus Limited
(ASX:AHZ) has announced it has received market approval for CardioCel® in the United Arab Emirates.
CardioCel® is used in cardiovascular repairs and reconstructions, with a key advantage being its resistance to calcification once inside the body.
The UAE has over 500 cases of congenital defects per annum, and is also an important regional hub for cardiovascular surgery.
Admedus has partnered with regional player Genpharm to bring CardioCel® to market, with the company indicating it has received first orders for the product following the market approval announcement.
Admedus Limited reported a net loss of $25 million at 30 June 2016.
